Triple-Drug attack aims to beat rare lymphoma
Disease control
Not yet recruiting
This phase 2 trial tests a combination of three drugs—golidocitinib, pegaspargase, and an immunotherapy—as a first treatment for advanced NK T-cell lymphoma, a rare and aggressive cancer. The study will enroll 40 people who have not had prior therapy. The goal is to see if this c…
Phase: PHASE2 • Sponsor: LIANG WANG • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC